Abeona Therapeutics Enrolls First Patient in Phase 2 for EB-101 Gene Therapy Clinical Trial for Epidermolysis Bullosa Sep 26, 2016
Abeona Therapeutics Announces Licensing of the AIM(TM) Next Generation AAV Gene Therapy Vector Platform From The University of North Carolina at Chapel Hill Sep 21, 2016
Abeona Therapeutics Announces Publication of Preclinical Data Supporting Clinical Translation of MPS IIIA Gene Therapy Sep 15, 2016
Abeona Therapeutics Enrolls 5th Patient in Phase 1/2 Gene Therapy Clinical Trial for Epidermolysis Bullosa Sep 8, 2016
Abeona Therapeutics to Present at Rodman & Renshaw 18th Annual Global Investment Conference Sep 7, 2016
Abeona Therapeutics to Present at Landmark Angels 6th Annual Investing for Cures 2016 Conference Sep 1, 2016
Abeona Therapeutics Completes Enrollment of Low-Dose Cohort for ABO-102 in Phase 1/2 Clinical Trial for MPS IIIA Patients Aug 29, 2016
Abeona Therapeutics Announces Second Quarter 2016 Financial Results and Recent Clinical Highlights Aug 16, 2016
